Zoetis Inc. Cash and Cash Equivalents
Zoetis Inc. (ZTS) had Cash and Cash Equivalents of $1.48 billion as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-06
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $1.48B.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $1.94B.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $2.45B.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $2.08B.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $1.48B 10-Q · filed 2026-08-06 |
| 2026-03-31 | $1.94B 10-Q · filed 2026-05-07 |
| 2025-12-31 | $2.45B 10-Q · filed 2026-08-06 |
| 2025-09-30 | $2.08B 10-Q · filed 2025-11-04 |
| 2025-06-30 | $1.44B 10-Q · filed 2025-08-05 |
| 2025-03-31 | $1.72B 10-Q · filed 2025-05-06 |
| 2024-12-31 | $1.99B 10-Q · filed 2025-11-04 |
| 2024-09-30 | $1.71B 10-Q · filed 2024-11-04 |
| 2024-06-30 | $1.57B 10-Q · filed 2024-08-06 |
| 2024-03-31 | $1.98B 10-Q · filed 2024-05-02 |
| 2023-12-31 | $2.04B 10-Q · filed 2024-11-04 |
| 2023-09-30 | $1.75B 10-Q · filed 2023-11-02 |
| 2023-06-30 | $1.72B 10-Q · filed 2023-08-08 |
| 2023-03-31 | $2.11B 10-Q · filed 2023-05-04 |
| 2022-12-31 | $3.58B 10-Q · filed 2023-11-02 |
| 2022-09-30 | $2.51B 10-Q · filed 2022-11-03 |
| 2022-06-30 | $2.65B 10-Q · filed 2022-08-04 |
| 2022-03-31 | $3.13B 10-Q · filed 2022-05-05 |
| 2021-12-31 | $3.48B 10-Q · filed 2022-11-03 |
| 2021-09-30 | $3.27B 10-Q · filed 2021-11-04 |
| 2021-06-30 | $3.66B 10-Q · filed 2021-08-05 |
| 2021-03-31 | $3.60B 10-Q · filed 2021-05-06 |
| 2020-12-31 | $3.60B 10-Q · filed 2021-11-04 |
| 2020-09-30 | $3.65B 10-Q · filed 2020-11-05 |
| 2020-06-30 | $3.35B 10-Q · filed 2020-08-06 |
| 2020-03-31 | $1.95B 10-Q · filed 2020-05-06 |
| 2019-12-31 | $1.93B 10-Q · filed 2020-11-05 |
| 2019-09-30 | $1.81B 10-Q · filed 2019-11-07 |
| 2019-06-30 | $1.75B 10-Q · filed 2019-08-06 |
| 2019-03-31 | $1.73B 10-Q · filed 2019-05-02 |
| 2018-12-31 | $1.60B 10-Q · filed 2019-11-07 |
| 2018-09-30 | $1.29B 10-Q · filed 2019-11-07 |
| 2018-06-30 | $1.56B 10-Q · filed 2019-08-06 |
| 2018-03-31 | $1.65B 10-Q · filed 2019-05-02 |
| 2017-12-31 | $1.56B 10-Q · filed 2019-11-07 |
| 2017-10-01 | $1.98B 10-Q · filed 2018-11-01 |
| 2017-07-02 | $705.00M 10-Q · filed 2018-08-02 |
| 2017-04-02 | $629.00M 10-Q · filed 2018-05-02 |
| 2016-12-31 | $727.00M 10-Q · filed 2018-11-01 |
| 2016-10-02 | $651.00M 10-Q · filed 2017-11-02 |
| 2016-07-03 | $658.00M 10-Q · filed 2017-08-08 |
| 2016-04-03 | $675.00M 10-Q · filed 2017-05-04 |
| 2015-12-31 | $1.15B 10-K · filed 2018-02-15 |
| 2015-09-27 | $592.00M 10-Q · filed 2016-11-03 |
| 2015-06-28 | $544.00M 10-Q · filed 2016-08-05 |
| 2015-03-29 | $559.00M 10-Q · filed 2016-05-06 |
| 2014-12-31 | $882.00M 10-K · filed 2018-02-15 |
| 2014-09-28 | $598.00M 10-Q · filed 2015-11-05 |
| 2014-06-29 | $578.00M 10-Q · filed 2015-08-06 |
| 2014-03-30 | $506.00M 10-Q · filed 2015-05-07 |
| 2013-12-31 | $610.00M 10-K · filed 2017-02-16 |
| 2013-09-29 | $389.00M 10-Q · filed 2014-11-10 |
| 2013-06-30 | $369.00M 10-Q · filed 2014-08-12 |
| 2013-03-31 | $468.00M 10-Q · filed 2014-05-13 |
| 2012-12-31 | $317.00M 10-K · filed 2016-02-24 |
| 2012-09-30 | $133.00M 10-Q · filed 2013-11-13 |
| 2012-07-01 | $106.00M 10-Q · filed 2013-08-14 |
| 2012-04-01 | $113.00M 10-Q · filed 2013-05-15 |
| 2011-12-31 | $79.00M 10-K · filed 2015-02-27 |
| 2010-12-31 | $63.00M 10-K · filed 2014-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |